Mood stabilizers: Insights from users' perceptions
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2025.119753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von M F Tagni und 8 weiteren Autor:innen. Beteiligte Einrichtung: AREA, Asistencia e Investigación en Trastornos del Ánimo, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Bipolar Disorder, Antimanic Agents, Antipsychotic Agents, Patient Satisfaction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Opinions and subjective perceptions regarding psychopharmacological treatment have proven to be strong predictors of quality of life, adherence, and general outcomes, as well as a rich source of data for research. Although mood stabilizing agents (MSA) represent the cornerstone of the treatment of bipolar disorders (BDs), data on the experiences of patients undergoing treatment with these drugs are scarce. We aimed to explore and compare user-reported data on four first-line MSA and identify predictors of treatment satisfaction. METHODS: We conducted a quantitative analysis of a random sample of 200 posts specifically related to first-line mood stabilizers (lithium, lamotrigine, valproate, and quetiapine) from individuals undergoing long-term treatment for BDs. Demographical, clinical, somatic, and emotional/psychological side-effects and treatment-related data were analyzed. RESULTS: This study found that the reported levels of satisfaction with MSAs were notably high. Lamotrigine received higher satisfaction ratings than quetiapine and valproate, after including age, sex, dose, and length of treatment in the models. Lithium was rated higher than valproate and quetiapine, although this difference did not reach statistical significance. Obsessive-compulsive symptoms, emotional hyperreactivity, cognitive symptoms, anxiety, weight gain, and gastrointestinal symptoms emerged as significant predictors of treatment dissatisfaction. CONCLUSIONS: The findings of this study underscore the significant role that emotional and psychological side effects play in treatment dissatisfaction during MSA use. Both research and clinical decisions should consider the subjective experiences of patients undergoing MSA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AREA, Asistencia e Investigación en Trastornos del Ánimo, Buenos Aires, Argentina.
- AREA, Asistencia e Investigación en Trastornos del Ánimo, Buenos Aires, Argentina. Electronic address: sstreji@gmail.com.
- Department of Epidemiology, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA. Electronic address: aszmulewicz@hsph.harvard.edu.
Zitieren
APA
Tagni, M. F., Strejilevich, S. A., Camino, S., Carballo, E., Guglielmetti, M., López Escalona, L., Oppel, M., Sabattini, L., & Szmulewicz, A. (2025). Mood stabilizers: Insights from users' perceptions. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.119753
Vancouver
Tagni MF, Strejilevich SA, Camino S, Carballo E, Guglielmetti M, López Escalona L, et al. Mood stabilizers: Insights from users' perceptions. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.119753
BibTeX
@article{Tagni2025,
author = {Tagni, M F and Strejilevich, S A and Camino, S and Carballo, E and Guglielmetti, M and López Escalona, L and Oppel, M and Sabattini, L and Szmulewicz, A},
title = {Mood stabilizers: Insights from users' perceptions},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2025.119753}
}
EUVIMED